October 20, 2023 07:14 AM EDTUpdated 10:43 AM
Deals

#ES­MO23 dis­patch: What to know about the HER3 ADC that got Mer­ck to pay $2B cash

Reynald Castañeda

Deputy Editor

MADRID — Among the three an­ti­body-drug con­ju­gates from Mer­ck’s deal with Dai­ichi Sankyo, pa­tri­tum­ab derux­te­can takes up the largest por­tion of the $4 bil­lion up­front at $2 bil­lion. It is al­so the most ad­vanced, with a BLA slat­ed for 2024. To learn more about the HER3-tar­get­ing as­set, End­points News spoke to pa­tri­tum­ab in­ves­ti­ga­tor Pasi Jänne on the side­lines of the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy in Madrid.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

House to mark up bill tar­get­ing Chi­nese biotech and ge­nomics com­pa­nies

Am­gen touts new da­ta for obe­si­ty drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

No­var­tis makes a $1B ra­dio­phar­ma deal, buy­ing Mar­i­ana On­col­o­gy

J&J show­cas­es more blad­der can­cer re­sults from 'pret­zel' drug-de­vice com­bo

CG On­col­o­gy touts in­ter­im Phase 3 blad­der can­cer da­ta, gears up to com­pete with Im­mu­ni­ty­Bio

sponsored

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

A service from the Financial Times